Quantum Biopharma LTD Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
SCHEDULE 13D/A: Malone Wealth Ventures Discloses 17.8% Stake in Quantum Biopharma, Advisor Kevin Malone Increases Holdings
Malone Wealth Ventures LLC and its President and CEO, Kevin Malone, have disclosed a beneficial ownership of 17.8% of Quantum Biopharma Ltd.'s common stock, with Mr. Malone also serving as an Advisor to the Board.
NASDAQ
SCHEDULE 13D/A: Malone Wealth Ventures Increases Stake in Quantum Biopharma to 17%, Advisor Kevin Malone Expands Influence
Malone Wealth Ventures LLC and its President Kevin Malone have increased their beneficial ownership in Quantum Biopharma Ltd. to 17% through open market purchases and compensation grants, indicating potential influence over the issuer's strategic direction.
NASDAQ
Malone Wealth Ventures LLC has filed an amended Schedule 13D, revealing a beneficial ownership of 14.8% of Quantum Biopharma Ltd.'s common stock.
NASDAQ
SCHEDULE 13D: Malone Wealth Ventures Discloses 14.6% Stake in Quantum Biopharma, CEO Joins Advisory Board
Malone Wealth Ventures LLC has disclosed a 14.6% beneficial ownership stake in Quantum Biopharma Ltd., acquired for investment purposes, with its CEO also serving as an advisor to the issuer's board.